US EditionPublished • loading... • Updated
Dark Blue Therapeutics acquired by Amgen for up to $840 million
Amgen's $840 million acquisition adds a novel protein degrader targeting MLLT1/3 proteins to its leukemia pipeline, aiming to improve treatment resistance and remission durability.
- On Jan. 6, 2026, Amgen announced it acquired Dark Blue Therapeutics, a biotechnology company headquartered in Oxford, England, in a deal valued at up to $840 million.
- Dark Blue Therapeutics spun out of Oxford University research in 2020 and was backed by Oxford Science Enterprises, Bristol Myers Squibb and Evotec.
- The MLLT1/3 degrader candidate, DBT 3757, is designed to degrade MLLT1 and MLLT3 proteins driving AML, with preclinical data showing strong anti-cancer activity and potential for combination use.
- Amgen will integrate Dark Blue into its research organization, strengthening oncology discovery; the companies did not disclose the upfront payment, with BofA Securities and Goodwin Procter advising Dark Blue.
- The acquisition positions Amgen to add a first-in-class MLLT1/3 degrader programme amid growing targeted protein degradation interest in recent years.
Insights by Ground AI
11 Articles
11 Articles
Coverage Details
Total News Sources11
Leaning Left2Leaning Right0Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
